Table 3.
Changes in central foveal thickness in the low-fluence group and half-dose verteporfin group after photodynamic therapy
| Time point | CFT (μm) | Low-fluence group (34 patients, 36 eyes) | Half-dose group (26 patients, 28 eyes) | P-value* |
|---|---|---|---|---|
| Baseline | Mean ± SD | 351±90 | 341±96 | – |
| Min, median, max | 208, 367, 640 | 210, 342, 525 | 0.685 | |
| 1 month | Mean ± SD | 194±59 | 180±43 | – |
| Min, median, max | 110, 215, 377 | 119, 192, 312 | 0.802 | |
| 3 months | Mean ± SD | 190±65 | 178±48 | – |
| Min, median, max | 111, 208, 418 | 126, 189, 333 | 0.846 | |
| 6 months | Mean ± SD | 181±41 | 176±50 | – |
| Min, median, max | 103, 215, 398 | 130, 187, 325 | 0.758 | |
| Last visit | Mean ± SD | 188±61 | 181±47 | – |
| Min, median, max | 108, 204, 411 | 119, 190, 306 | 0.943 |
Note:
*
P-value based on Wilcoxon signed rank test of median difference equal to zero.
Abbreviations: BCVA, best corrected visual acuity; CFT, central foveal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; max, maximum; min, minimum; SD, standard deviation.